This summary is generated by an algorithm. If you find any mistakes, let us know.

Apps Consumer Health Care Health Diagnostics Medical Device mHealth North America

TytoCare Raises Additional $50M in Extended Series D Funding

– TytoCare is a NYC-based healthcare industry’s modular device and telehealth platform for AI-powered, on-demand remote medical examinations.
– The company raised $50M in a Series D extension round.
– The extension round was led by Insight Partners with participation from new growth investors Tiger Global Management and Qumra Capital and existing investors Qualcomm Ventures LLC, Olive Tree Ventures, and Shenzhen Capital Group Company.

Source
Europe Health Care Health Diagnostics Machine Learning

ClinSpec Diagnostics Closes £3.5M Funding

– ClinSpec Diagnostics is a Glasgow, Scotland, UK-based developer of liquid biopsies for early detection of cancer.
– The company raised £3.5M in funding led by Norcliffe Capital Limited, the University of Strathclyde, Eos Advisory and the founders.
– The first tranche of the investment (£2.4M) was secured in 2020 led by Mercia’s EIS Funds with Scottish Enterprise, profit with purpose investor SIS Ventures, Eos Advisory and the University of Strathclyde.

Source
Biotechnology Health Care Health Diagnostics North America Therapeutics

Century Therapeutics Closes $160M Series C Financing

– Century Therapeutics, a Philadelphia, PA-based cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, closed a $160m Series C financing.
– The round was led by Casdin Capital and brought together a syndicate of new investors including Fidelity Management & Research LLC, the Federated Hermes Kauffmann Funds, RA Capital, Logos Capital, OrbiMed, Marshall Wace, Qatar Investment Authority, Avidity Partners, and Octagon Capital.
– Eli Casdin, Founder and Chief Investment Officer of Casdin Capital will be joining the Century Therapeutics Board of Directors.

Source
Health Diagnostics North America Pharmaceutical Therapeutics

Janux Therapeutics Announces $56 Million Series A to Advance Novel Cancer Drug Candidates Using T Cell Engager (TRACTr) Technology

– Janux Therapeutics announced the close of a $56m Series A financing.
– The financing was led by Avalon Ventures and joined by new investors, OrbiMed and RA Capital Management, as well as existing investors, Bregua and Correlation Ventures.
– In conjunction with the financing, Peter Thompson, M.D., partner at OrbiMed, and Jake Simson, Ph.D., partner at RA Capital Management, will join the Board of Directors.
– Janux’s proprietary Tumor Activated T Cell Engager (TRACTr) technology is designed to overcome specific limitations of current T cell immuno-oncology therapies.

Source
Biotechnology Health Care Health Diagnostics Life Science Medical Device North America

Truvian Sciences Raises More Than $105M in Series C Financing

– Truvian Sciences, a San Diego, CA-based closed more than $105m in a Series C financing.
– The round was led by TYH Ventures, Glen Tullman of 7wireVentures, and Wittington Ventures.
– The company intends to use the funds to advance development of its automated benchtop blood testing system, paving the way to submit the device for U.S. Food and Drug Administration (FDA) clearance, and to scale its team in preparation for broad commercialization.
– Truvian is a healthcare company at the intersection of diagnostics and consumer technology.

Source
Biotechnology Health Care Health Diagnostics Life Science Medical Device North America

Truvian raises $105 million to commercialize its automated blood-testing platform

– San Diego, California-based Truvian, a startup developing blood-testing technology that leans heavily on automation, today announced the close of an over $105 million oversubscribed series C round led by TYH Ventures, 7wireVentures’ Glen Tullman, and Wittington Ventures.
– Truvian says the funds will advance development of its benchtop blood testing system and enable the company to grow its product development team.
– More than 13 billion tests are performed in over 250,000 labs in the U.S. each year, and errors related to lab testing are more common than you might think. A 2014 study estimated that diagnostic errors for U.S. outpatients occur about 12 million times per year.

Source
Biotechnology Health Care Health Diagnostics Information Technology North America

Miroculus Closes Extension to $45M Series B Financing

– Miroculus, Inc. announced the completion of a Series B extension, bringing the total capital raised in the series to $45M.
– The round included the addition of two venture capital firms, Cota Capital, who led the round, and Section 32.
– Miroculus is a developer of revolutionary tools for personal lab automation.
– The company’s first system, Miro Canvas, will be launched this fall.

Source
Biotechnology Health Care Health Diagnostics North America Therapeutics

Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline

– Xilio Therapeutics, a biotechnology company developing potent, tumor-selective immunotherapies for patients with cancer, today announced the successful closing of a $95m Series C financing.
– Proceeds from the financing will be used to advance Xilio’s lead therapeutic candidates, XTX202 (tumor-selective IL-2) and XTX101 (tumor-selective anti-CTLA4 mAb), into clinical trials.
– Investigational new drug (IND) applications for XTX202 and XTX101 are expected to be filed with the U.S. Food and Drug Administration (FDA) in 2021.
– The financing was led by Rock Springs Capital and was joined by Bain Capital Life Sciences, Deerfield Management Company and RA Capital Management, among other new investors.

Source
Biotechnology Health Care Health Diagnostics Life Science North America

Micronoma Closes $3.5M Convertible Debt Financing Round

– Micronoma is a San Diego, Calif.-based cancer detection biotech company that utilizes signals from the tumor-related microbiome to diagnose cancer at an early stage with liquid biopsy technology.
– The company closed a $3.5m convertible debt financing round.
– Backers included SymBiosis, LLC and The Seerave Foundation.
– The investments bring the company’s total amount of funding to $6.5m since the first seed round six months ago.

Source
Biotechnology Health Care Health Diagnostics Life Science North America

Fred Hutch biotech spinout Ozette raises $6M from Madrona, AI2, Vulcan

– Ozette, a biotech company, raised $6m in seed funding.
– The round was led by Madrona Venture Group and joined by AI2 and Vulcan.
– The company has eight employees with plans to double that number in the next few months with the fresh cash.
– Ozette’s founders estimate that in the past, researchers were able to analyze 10% of the information revealed by their studies. Their tool brings that up to 100%.

Source
Crunchbase icon

Content report

The following text will be sent to our editors: